Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Treatments: Antibodies; Antibodies, Monoclonal; Immunoglobulins; Rituximab

Criteria

Inclusion Criteria:

• Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's macroglobulinemia